Securian Asset Management Inc. Has $667,000 Holdings in Align Technology, Inc. $ALGN

Securian Asset Management Inc. lessened its position in Align Technology, Inc. (NASDAQ:ALGN) by 2.8% in the second quarter, HoldingsChannel reports. The fund owned 3,521 shares of the medical equipment provider’s stock after selling 100 shares during the quarter. Securian Asset Management Inc.’s holdings in Align Technology were worth $667,000 as of its most recent SEC filing.

Several other hedge funds also recently modified their holdings of the stock. Wealth Enhancement Advisory Services LLC boosted its position in Align Technology by 44.3% in the first quarter. Wealth Enhancement Advisory Services LLC now owns 9,380 shares of the medical equipment provider’s stock worth $1,490,000 after purchasing an additional 2,881 shares during the last quarter. Janney Montgomery Scott LLC boosted its position in Align Technology by 48.9% in the first quarter. Janney Montgomery Scott LLC now owns 10,120 shares of the medical equipment provider’s stock worth $1,608,000 after purchasing an additional 3,325 shares during the last quarter. Oppenheimer & Co. Inc. boosted its position in Align Technology by 2.3% in the first quarter. Oppenheimer & Co. Inc. now owns 10,570 shares of the medical equipment provider’s stock worth $1,679,000 after purchasing an additional 241 shares during the last quarter. Asset Management One Co. Ltd. boosted its position in Align Technology by 14.5% in the first quarter. Asset Management One Co. Ltd. now owns 31,624 shares of the medical equipment provider’s stock worth $5,024,000 after purchasing an additional 4,009 shares during the last quarter. Finally, Robeco Institutional Asset Management B.V. boosted its position in Align Technology by 69.7% in the first quarter. Robeco Institutional Asset Management B.V. now owns 37,336 shares of the medical equipment provider’s stock worth $5,931,000 after purchasing an additional 15,329 shares during the last quarter. Hedge funds and other institutional investors own 88.43% of the company’s stock.

Insiders Place Their Bets

In other Align Technology news, CEO Joseph M. Hogan bought 7,576 shares of the firm’s stock in a transaction on Friday, August 1st. The shares were acquired at an average cost of $131.49 per share, for a total transaction of $996,168.24. Following the purchase, the chief executive officer directly owned 184,945 shares of the company’s stock, valued at $24,318,418.05. The trade was a 4.27% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 0.66% of the stock is owned by corporate insiders.

Align Technology Stock Performance

NASDAQ:ALGN opened at $135.21 on Friday. Align Technology, Inc. has a 52-week low of $122.00 and a 52-week high of $246.19. The firm has a market cap of $9.80 billion, a price-to-earnings ratio of 22.80, a PEG ratio of 1.54 and a beta of 1.70. The business’s fifty day moving average is $134.14 and its 200 day moving average is $162.67.

Align Technology (NASDAQ:ALGN) last released its quarterly earnings data on Wednesday, July 30th. The medical equipment provider reported $2.49 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $2.57 by ($0.08). Align Technology had a net margin of 11.04% and a return on equity of 13.36%. The company had revenue of $1.01 billion for the quarter, compared to the consensus estimate of $1.06 billion. During the same quarter in the previous year, the firm posted $2.41 earnings per share. The business’s revenue for the quarter was down 1.6% compared to the same quarter last year. Align Technology has set its Q3 2025 guidance at EPS. Equities analysts predict that Align Technology, Inc. will post 7.98 EPS for the current fiscal year.

Align Technology declared that its board has initiated a share repurchase program on Tuesday, August 5th that permits the company to repurchase $200.00 million in shares. This repurchase authorization permits the medical equipment provider to repurchase up to 2% of its stock through open market purchases. Stock repurchase programs are often a sign that the company’s management believes its shares are undervalued.

Wall Street Analysts Forecast Growth

Several research analysts have weighed in on ALGN shares. Evercore ISI cut their price objective on Align Technology from $170.00 to $160.00 and set an “outperform” rating on the stock in a research report on Wednesday, October 8th. Jefferies Financial Group reissued a “hold” rating and issued a $140.00 price objective (down previously from $215.00) on shares of Align Technology in a research report on Friday, October 10th. Stifel Nicolaus cut their price objective on Align Technology from $275.00 to $200.00 and set a “buy” rating on the stock in a research report on Thursday, July 31st. UBS Group cut their price objective on Align Technology from $160.00 to $155.00 and set a “neutral” rating on the stock in a research report on Thursday, October 16th. Finally, Wells Fargo & Company lowered their target price on Align Technology from $246.00 to $199.00 and set an “overweight” rating on the stock in a research note on Thursday, July 31st. One analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, seven have issued a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat, the company has an average rating of “Hold” and a consensus price target of $173.09.

About Align Technology

Align Technology, Inc designs, manufactures, and markets Invisalign clear aligners, and iTero intraoral scanners and services for orthodontists and general practitioner dentists in the United States, Switzerland, and internationally. The company's Clear Aligner segment offers comprehensive products, including Invisalign comprehensive package that addresses the orthodontic needs of younger patients, such as mandibular advancement, compliance indicators, and compensation for tooth eruption; and Invisalign First Phase I and Invisalign First Comprehensive Phase 2 package for younger patients generally between the ages of six and ten years, which is a mixture of primary/baby and permanent teeth.